Navigation Links
New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients
Date:6/28/2011

SAN DIEGO, June 28, 2011 /PRNewswire/ -- Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart failure.  The study was released in the June 21 edition of the Journal of the American College of Cardiology.

(Photo: http://photos.prnewswire.com/prnh/20110628/LA27443)

The study's lead author, Robert M. Adamson, MD, medical director of the cardiac transplantation program at Sharp Memorial, and colleagues concluded that LVAD therapy should be considered an "attractive option" for some patients, and that advanced age alone should not determine whether or not a patient receives LVAD support.  The research team also noted that "very good results can be achieved in a community hospital setting with a focused effort from a dedicated team."

Patients in the study were implanted with Thoratec's HeartMate II LVAD, which received FDA approval for bridge to transplantation therapy in April 2008 and for destination therapy in January 2010 for transplant-ineligible heart-failure patients.  At Sharp Memorial, which serves as a Thoratec training site, the transplant team has implanted nearly 130 HeartMate II devices.  The physicians and staff there have been working together since the 1980s and performed San Diego's first heart transplant in 1985.  Since then, the team has performed more than 340 heart transplants and numerous implant procedures.  They also have the longest LVAD-supported patient in the world, who first received the device more than nine years ago in March 2002.  

"With an increasing population of elderly patients with advanced heart failure who have limited treatment options, the FDA's approval of LVAD therapy make sense for many individuals," said Dr. Adamson.  "Older patients in the study were very appreciative of the improved quality of life afforded by LVAD therapy.  While younger patients want to live longer, older patients want to live better."

During the research period, 55 patients received the HeartMate II between Oct. 5, 2005, and Jan. 1, 2010, as part of either bridge to transplantation or destination therapy trials. Patients were separated into two age groups: 70 years of age or younger (30 patients) and older than 70 years of age (25 patients). Pre-operatively, all patients were classified as having severe heart failure, showing symptoms of cardiac insufficiency at rest (New York Heart Association Class IV). The research team compared outcome measures between the two groups including survival, length of hospital stay, adverse events and quality of life.

The survival rate between the two groups was not statistically different.  For patients older than 70, the survival rate was 97 percent at one month, 75 percent at one year and 70 percent at two years.  For patients 70 and younger, the rate was 96 percent at one month, 72 percent at one year and 65 percent at two years.  

The average length of hospital stay for the older group was 24 days, which was similar to length of stay for the younger group (23 days). The researchers found no differences in the incidence of adverse events between the two groups, and quality of life and functional status improved significantly in both groups.

Co-authors of the study at Sharp Memorial include Marcia Stahovich, RN; Suzanne Chillcott, BSN; Sam Baradarian, MD; Joseph Chammas, MD; Brian Jaski, MD; Peter Hoagland, MD and Walter Dembitsky, MD.

About Sharp Memorial Hospital

Sharp Memorial Hospital, which first opened its doors in 1955, is part of Sharp HealthCare, San Diego's most comprehensive health care delivery system, recognized for clinical excellence in cardiac care, women's services, cancer, orthopedics, multi-organ transplants, rehabilitation and behavioral health services. To learn more about Sharp Memorial, visit www.sharp.com/memorial or call 1-800-82-SHARP (1-800-827-4277).


'/>"/>
SOURCE Sharp HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology:
(Date:2/25/2017)... CA (PRWEB) , ... February 25, 2017 , ... FCPX ... ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total control ... to easily refine their color range. With color spectrum tools users can visually see ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Indiana Fiber Network ... the company later this year. Dyer started as the Chairman of the Management ... the establishment of the corporation including the recruitment of investor/owners and development of the ...
Breaking Medicine News(10 mins):